University of California San Francisco

David M. Jablons - 144
David
Jablons
MD, FACS

Professor and Chief, UCSF General Thoracic Surgery
Nan T. McEvoy Distinguished Professor of Thoracic Surgical Oncology
Ada Distinguished Professor of Thoracic Oncology
Program Leader Thoracic Oncology
Director, Thoracic Oncology Laboratory, UCSF Helen Diller Family Comprehensive Cancer Center

Academic Office:
500 Parnassus Ave, MUW 405, Box 0118
San Francisco, CA 94143-0118
Tel: (415) 353-8890
Email: [email protected] 
Admin: [email protected] 

Thoracic Surgery & Oncology Program 
1600 Divisadero St., 4th Floor, Box 1705
San Francisco, CA 94115
Tel: 415-885-3882

Biography

David M. Jablons M.D., FACS is Professor and Chief of the Section of General Thoracic Surgery at UCSF, and Program Leader of Thoracic Oncology. Dr. Jablons is also Ada Distinguished Professor in Thoracic Oncology and Nan T. McEvoy Distinguished Professor of Thoracic Surgical Oncology. Dr. Jablons is Director of the Thoracic Oncology Lab, one of the largest in the Department of Surgery, with seven principal investigators, an enviable portfolio of NIH grants, and state-of-art-equipment. Utilizing next generation sequencing and leveraging one of the largest thoracic tissue banks in the world, the lab has compiled an enviable record of scientific discovery and invention including a life-saving prognostic assay that informs the decision for providing adjuvant therapy to early-stage lung cancer patients.

Dr. Jablons received his medical degree from Albany Medical College. During medical school, he was awarded an NCI preceptorship allowing him to train under Steven Rosenberg, a world-renowned surgeon and tumor immunologist. This experience kindled Dr. Jablons lifelong interest in translational and precision medicine. Dr. Jablons then completed his general surgery residency at Tufts-New England Medical Center and his thoracic surgery residency at what is now New York Presbyterian-Weill Cornell Medical Center. His mentors included Robert Ginsburg at Memorial Sloan-Kettering and David Sugarbaker at Brigham & Women's Hospital, both world-renown thoracic surgical oncologists. Dr. Jablons also served as a Navy commander while Chief of Thoracic Surgery at the Oakland Naval Hospital. In 1997, he was named Chief of General Thoracic Surgery at UCSF.

Dr. Jablons is a highly accomplished thoracic surgeon, widely sought out by patients in the Bay Area and world-wide. One patient, Bonnie J. Addario, after recovering from an arduous lung cancer surgery, started a foundation bearing her name she co-founded with Dr. Jablons. Today, the Addario Foundation is one of the leading underwriters of lung cancer research. Dr. Jablons has also been a dedicated teacher and outstanding mentor for both for clinical fellows and surgical residents, the latter including Dan Raz and Johannes Kratz, protégés with an enviable and prolific record of publications who helped spearhead development of predictive and prognostic tools for lung cancer treatment in the lab.

Dr. Jablons has been a trailblazer in educational outreach, co-founding the UCSF Thoracic Oncology Conference, an annual symposium that provided expert training for thousands of community surgeons for over a decade. He also was instrumental in establishing the China Clinical Trials Consortium to find more effective treatments for lung cancer, and to ameliorate the epidemic of lung cancer in China. In 2009, he led the effort to bring World Conference on Lung Cancer to San Francisco, the preeminent event in the field, in which he served as co-Chair.

He is a member of numerous professional organizations including the Society of Thoracic Surgeons, the American College of Chest Physicians, the American Association for Cancer Research and the International Association for the Study of Lung Cancer (IASLC). Highly respected by his peers, Dr. Jablons was named to the list of U.S. News "America's Top Doctors," a distinction reserved for the top 1% of physicians in the nation for a given specialty. Dr. Jablons was recently inducted into the American Surgical Society, the nation's most prestigious.

Awards & Honors

Award Conferred By Date
Surgical Resident Teaching Award University of California, San Francisco 2001
Surgical Resident Teaching Award University of California, San Francisco 1999

Education

Education

Yale University, B.A., American Literature, 1979

Albany Medical College of Union University, M.D., 1984

Residencies

Oak Knoll Naval Hospital, Oakland, CA, General Surgery, 1984-85 

Tufts University/New England Medical Center, General Surgery, 1985-86, 89-91

Weill Cornell University Medical Center, Cardiothoracic Surgery, 1991-93

Fellowships

NCI/NIH, Surgery Branch, Surgical Oncology, 1986-89

Brigham & Women's Hospital, Lung Transplantation, 1992 

New York Hospital/Memorial Sloan Kettering Cancer Center, Thoracic Surgery, 1992-93

Board Certifications

American Board of Surgery

American Board of Thoracic Surgery

Clinical Expertise

Bronchioloalveolar Carcinoma (BAC)
Carcinoid Tumors
Chest Wall Tumors
Esophageal Cancer
Esophagectomy
Lung Metastases
Lung Transplantation
Lung Volume Reduction Surgery
Malignant Mesothelioma
Mediastinal Masses

Robotic Thoracic Surgery

Minimally Invasive Thoracic Surgery
Non-Small Cell Lung Cancer
Sarcomas
Small Cell Lung Cancer
Thymoma & Thymic Carcinoma
Tracheal Tumors
Video-Assisted Thoracoscopic Surgery (VATS)

Program Affiliations

Thoracic Oncology Program

Member, UCSF Helen Diller Family Comprehensive Cancer Center

Grants and Funding

  • Inflammation and Lung Carcinogenesis | NIH | 2008-05-01 - 2014-03-31 | Role: Principal Investigator
  • The Wnt Pathway in Malignant Mesothelioma | NIH | 2005-03-01 - 2010-02-28 | Role: Principal Investigator

Research Narrative

The Thoracic Oncology Lab focuses on drug target discovery, commercialization of novel therapeutics and development of genomic assays based on predictive and prognostic biomarkers.

Research Interests

Early Detection and Screening
Prognostic molecular multi-gene assays in Early-Stage NSCLC
Discovery of novel therapeutic targets in in thoracic malignancies
Investigation of signal transduction pathways including Wnt, Hedgehog, and Hippo in lung cancer and mesothelioma
Isolation of lung cancer stems cells
Inflammation in lung carcinogenesis
Study of "systems genetics" in thoracic malignancies
Next generation sequencing
Clinical outcomes research
Lung cancer epigenetics and emerging biomarkers

Research Pathways

Basic Biomedical & Translational Research

Publications

MOST RECENT PUBLICATIONS FROM A TOTAL OF 266
  1. Novel dual action PARP and microtubule polymerization inhibitor AMXI-5001 powerfully inhibits growth of esophageal carcinoma both alone and in combination with radiotherapy.
    Brand NR, Yang YW, Ding V, Dutta H, Peto CJ, Lemjabbar-Alaoui H, Jablons DM| | View in PubMed
  2. Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer.
    Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF, Gaudreault J, Damico LA, Holmgren E, Kabbinavar F| | View in PubMed
  3. Comparative genomics between matched solid and lepidic portions of semi-solid lung adenocarcinomas.
    Woodard GA, Ding V, Cho C, Brand NR, Kratz JR, Jones KD, Jablons DM| | View in PubMed
  4. SARS-CoV-2 infection of airway organoids reveals conserved use of Tetraspanin-8 by Ancestral, Delta, and Omicron variants.
    Hysenaj L, Little S, Kulhanek K, Magnen M, Bahl K, Gbenedio OM, Prinz M, Rodriguez L, Andersen C, Rao AA, Shen A, Lone JC, Lupin-Jimenez LC, Bonser LR, Serwas NK, Mick E, Khalid MM, Taha TY, Kumar R, Li JZ, Ding VW, Matsumoto S, Maishan M, Sreekumar B, Simoneau C, Nazarenko I, Tomlinson MG, Khan K, von Gottberg A, Sigal A, Looney MR, Fragiadakis GK, Jablons DM, Langelier CR, Matthay M, Krummel M, Erle DJ, Combes AJ, Sil A, Ott M, Kratz JR, Roose JP| | View in PubMed
  5. MK256 is a novel CDK8 inhibitor with potent antitumor activity in AML through downregulation of the STAT pathway.
    Lee JC, Liu S, Wang Y, Liang Y, Jablons DM| | View in PubMed
  6. Genetic and immunologic features of recurrent stage I lung adenocarcinoma.
    Kratz JR, Li JZ, Tsui J, Lee JC, Ding VW, Rao AA, Mann MJ, Chan V, Combes AJ, Krummel MF, Jablons DM| | View in PubMed
  7. Perioperative Lung Resection Outcomes After Implementation of a Multidisciplinary, Evidence-based Thoracic ERAS Program.
    Haro GJ, Sheu B, Marcus SG, Sarin A, Campbell L, Jablons DM, Kratz JR| | View in PubMed
  8. The effect of cullin 4A on lung cancer cell chemosensitivity to paclitaxel through p33ING1b regulation.
    Lung J, Chen YC, Lin YC, Li YC, You L, Jablons DM, Mao JH, Yang CT, Hung MS| | View in PubMed
  9. Improved outcomes and staging in non-small-cell lung cancer guided by a molecular assay.
    Gupta AR, Woodard GA, Jablons DM, Mann MJ, Kratz JR| | View in PubMed
  10. Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early-Stage Non-Squamous Non-Small Cell Lung Cancer Patients at Risk for Recurrence and Likely to Benefit From Adjuvant Chemotherapy.
    Woodard GA, Kratz JR, Haro G, Gubens MA, Blakely CM, Jones KD, Mann MJ, Jablons DM| | View in PubMed
  11. SARS-CoV-2 infection studies in lung organoids identify TSPAN8 as novel mediator.
    Hysenaj L, Little S, Kulhanek K, Gbenedio OM, Rodriguez L, Shen A, Lone JC, Lupin-Jimenez LC, Bonser LR, Serwas NK, Bahl K, Mick E, Li JZ, Ding VW, Matsumoto S, Maishan M, Simoneau C, Fragiadakis G, Jablons DM, Langelier CR, Matthay M, Ott M, Krummel M, Combes AJ, Sil A, Erle DJ, Kratz JR, Roose JP| | View in PubMed
  12. Extracellular sulfatases as potential blood-based biomarkers for early detection of lung cancer.
    Yang YW, Jablons DM, Lemjabbar-Alaoui H| | View in PubMed
  13. Resectability, Recurrence, and Risk Stratification of Giant Solitary Fibrous Tumors in the Thoracic Cavity.
    Woodard GA, Fels Elliott DR, Yap A, Haro GJ, Kratz JR, Mann MJ, Jones KD, Jablons DM| | View in PubMed
  14. Bioinformatic Approaches to Validation and Functional Analysis of 3D Lung Cancer Models.
    Li PJ, Roose JP, Jablons DM, Kratz JR| | View in PubMed
  15. A novel isoform of Homeodomain-interacting protein kinase-2 promotes YAP/TEAD transcriptional activity in NSCLC cells.
    Dai Y, Kyoyama H, Yang YL, Wang Y, Liu S, Wang Y, Mao JH, Xu Z, Uematsu K, Jablons DM, You L| | View in PubMed
  16. Development of novel monoclonal antibodies and immunoassays for sensitive and specific detection of SULF1 endosulfatase.
    Yang YW, Phillips JJ, Jablons DM, Lemjabbar-Alaoui H| | View in PubMed
  17. Ponatinib is a potential therapeutic approach for malignant pleural mesothelioma.
    Yang YW, Marrufo A, Chase J, Woodard GA, Jablons DM, Lemjabbar-Alaoui H| | View in PubMed
  18. Evaluation of a National Comprehensive Cancer Network Guidelines-Based Decision Support Tool in Patients With Non-Small Cell Lung Cancer: A Nonrandomized Clinical Trial.
    Wu SY, Lazar AA, Gubens MA, Blakely CM, Gottschalk AR, Jablons DM, Jahan TM, Wang VEH, Dunbar TL, Wong ML, Chan JW, Guthrie W, Belkora J, Yom SS| | View in PubMed
  19. Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing.
    Maynard A, McCoach CE, Rotow JK, Harris L, Haderk F, Kerr DL, Yu EA, Schenk EL, Tan W, Zee A, Tan M, Gui P, Lea T, Wu W, Urisman A, Jones K, Sit R, Kolli PK, Seeley E, Gesthalter Y, Le DD, Yamauchi KA, Naeger DM, Bandyopadhyay S, Shah K, Cech L, Thomas NJ, Gupta A, Gonzalez M, Do H, Tan L, Bacaltos B, Gomez-Sjoberg R, Gubens M, Jahan T, Kratz JR, Jablons D, Neff N, Doebele RC, Weissman J, Blakely CM, Darmanis S, Bivona TG| | View in PubMed
  20. AMXI-5001, a novel dual parp1/2 and microtubule polymerization inhibitor for the treatment of human cancers.
    Lemjabbar-Alaoui H, Peto CJ, Yang YW, Jablons DM| | View in PubMed
  21. The Crosstalk between Src and Hippo/YAP Signaling Pathways in Non-Small Cell Lung Cancer (NSCLC).
    Hsu PC, Yang CT, Jablons DM, You L| | View in PubMed
  22. Surgery for pleural mesothelioma, when it is indicated and why: arguments against surgery for malignant pleural mesothelioma.
    Woodard GA, Jablons DM| | View in PubMed
  23. Inhibition of cyclin-dependent kinase 7 down-regulates yes-associated protein expression in mesothelioma cells.
    Miao J, Kyoyama H, Liu L, Chan G, Wang Y, Urisman A, Yang YL, Liu S, Xu Z, Bin H, Li H, Jablons DM, You L| | View in PubMed
  24. Differential gene expression identifies KRT7 and MUC1 as potential metastasis-specific targets in sarcoma.
    Jiang L, Tolani B, Yeh CC, Fan Y, Reza JA, Horvai AE, Xia E, Kratz JR, Jablons DM, Mann MJ| | View in PubMed
  25. Case report: recurrent metastatic breast cancer in internal mammary dissection bed discovered at the time of coronary bypass.
    Woodard GA, Lee H, Fels Elliott DR, Jones KD, Wong J, Jablons DM, Ihnken K| | View in PubMed
  26. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).
    Hsu PC, Jablons DM, Yang CT, You L| | View in PubMed
  27. The crystal structure of the protein kinase HIPK2 reveals a unique architecture of its CMGC-insert region.
    Agnew C, Liu L, Liu S, Xu W, You L, Yeung W, Kannan N, Jablons D, Jura N| | View in PubMed
  28. Mesothelioma: Scientific clues for prevention, diagnosis, and therapy.
    Carbone M, Adusumilli PS, Alexander HR, Baas P, Bardelli F, Bononi A, Bueno R, Felley-Bosco E, Galateau-Salle F, Jablons D, Mansfield AS, Minaai M, de Perrot M, Pesavento P, Rusch V, Severson DT, Taioli E, Tsao A, Woodard G, Yang H, Zauderer MG, Pass HI| | View in PubMed
  29. Cucurbitacin E inhibits the Yes‑associated protein signaling pathway and suppresses brain metastasis of human non‑small cell lung cancer in a murine model.
    Hsu PC, Tian B, Yang YL, Wang YC, Liu S, Urisman A, Yang CT, Xu Z, Jablons DM, You L| | View in PubMed
  30. Cul4A Modulates Invasion and Metastasis of Lung Cancer Through Regulation of ANXA10.
    Hung MS, Chen YC, Lin P, Li YC, Hsu CC, Lung JH, You L, Xu Z, Mao JH, Jablons DM, Yang CT| | View in PubMed
  31. Incorporation of a Molecular Prognostic Classifier Improves Conventional Non-Small Cell Lung Cancer Staging.
    Kratz JR, Haro GJ, Cook NR, He J, Van Den Eeden SK, Woodard GA, Gubens MA, Jahan TM, Jones KD, Kim IJ, He B, Jablons DM, Mann MJ| | View in PubMed
  32. Applications of Next-Generation Sequencing in Neoantigen Prediction and Cancer Vaccine Development.
    Lancaster EM, Jablons D, Kratz JR| | View in PubMed
  33. The Role of Yes-Associated Protein (YAP) in Regulating Programmed Death-Ligand 1 (PD-L1) in Thoracic Cancer.
    Hsu PC, Yang CT, Jablons DM, You L| | View in PubMed
  34. Central Airway Obstruction Due to Tracheal Glomus Tumor.
    Haro GJ, Seeley EJ, Jablons DM, Kratz JR| | View in PubMed
  35. Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient With a MET Exon 14 Skipping Mutation.
    Rotow JK, Woodard GA, Urisman A, McCoach CE, Bivona TG, Elicker BM, Jablons DM, Blakely CM| | View in PubMed
  36. Scientific Advances and New Frontiers in Mesothelioma Therapeutics.
    Mutti L, Peikert T, Robinson BWS, Scherpereel A, Tsao AS, de Perrot M, Woodard GA, Jablons DM, Wiens J, Hirsch FR, Yang H, Carbone M, Thomas A, Hassan R| | View in PubMed
  37. Expansion of hedgehog disrupts mesenchymal identity and induces emphysema phenotype.
    Wang C, de Mochel NSR, Christenson SA, Cassandras M, Moon R, Brumwell AN, Byrnes LE, Li A, Yokosaki Y, Shan P, Sneddon JB, Jablons D, Lee PJ, Matthay MA, Chapman HA, Peng T| | View in PubMed
  38. Transfer of multiple loci of donor's genes to induce recipient tolerance in organ transplantation.
    Li T, Zhang W, Xu Q, Li S, Tong X, Ding J, Li H, Hou S, Xu Z, Jablons DM, You L| | View in PubMed
  39. Inhibition of yes-associated protein down-regulates PD-L1 (CD274) expression in human malignant pleural mesothelioma.
    Hsu PC, Miao J, Wang YC, Zhang WQ, Yang YL, Wang CW, Yang CT, Huang Z, You J, Xu Z, Jablons DM, You L| | View in PubMed
  40. Inhibition of yes-associated protein suppresses brain metastasis of human lung adenocarcinoma in a murine model.
    Hsu PC, Miao J, Huang Z, Yang YL, Xu Z, You J, Dai Y, Yeh CC, Chan G, Liu S, Urisman A, Yang CT, Jablons DM, You L| | View in PubMed
  41. Preclinical characterization of therapeutic antibodies targeted at the carboxy-terminus of Sonic hedgehog.
    Tolani B, Hoang NT, Acevedo LA, Giroux Leprieur E, Li H, He B, Jablons DM| | View in PubMed
  42. Old Sonic Hedgehog, new tricks: a new paradigm in thoracic malignancies.
    Giroux Leprieur E, Jablons DM, He B| | View in PubMed
  43. YAP regulates PD-L1 expression in human NSCLC cells.
    Miao J, Hsu PC, Yang YL, Xu Z, Dai Y, Wang Y, Chan G, Huang Z, Hu B, Li H, Jablons DM, You L| | View in PubMed
  44. Gli is activated and promotes epithelial-mesenchymal transition in human esophageal adenocarcinoma.
    Wang L, Jin JQ, Zhou Y, Tian Z, Jablons DM, He B| | View in PubMed
  45. Membrane-bound full-length Sonic Hedgehog identifies cancer stem cells in human non-small cell lung cancer.
    Giroux Leprieur E, Tolani B, Li H, Leguay F, Hoang NT, Acevedo LA, Jin JQ, Tseng HH, Yue D, Kim IJ, Wislez M, Wang C, Jablons DM, He B| | View in PubMed
  46. Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden.
    Wang VE, Urisman A, Albacker L, Ali S, Miller V, Aggarwal R, Jablons D| | View in PubMed
  47. Hippo pathway in lung development.
    Dai Y, Jablons D, You L| | View in PubMed
  48. Systematic comparison of two whole-genome amplification methods for targeted next-generation sequencing using frozen and FFPE normal and cancer tissues.
    Mendez P, Fang LT, Jablons DM, Kim IJ| | View in PubMed
  49. Drug development against the hippo pathway in mesothelioma.
    Woodard GA, Yang YL, You L, Jablons DM| | View in PubMed
  50. Adjuvant Chemotherapy Guided by Molecular Profiling and Improved Outcomes in Early Stage, Non-Small-Cell Lung Cancer.
    Woodard GA, Wang SX, Kratz JR, Zoon-Besselink CT, Chiang CY, Gubens MA, Jahan TM, Blakely CM, Jones KD, Mann MJ, Jablons DM| | View in PubMed
  51. DCLK1 is correlated with MET and ERK5 expression, and associated with prognosis in malignant pleural mesothelioma.
    Wang H, Dai YY, Zhang WQ, Hsu PC, Yang YL, Wang YC, Chan G, Au A, Xu ZD, Jiang SJ, Wang W, Jablons DM, You L| | View in PubMed
  52. Targeting YAP in malignant pleural mesothelioma.
    Zhang WQ, Dai YY, Hsu PC, Wang H, Cheng L, Yang YL, Wang YC, Xu ZD, Liu S, Chan G, Hu B, Li H, Jablons DM, You L| | View in PubMed
  53. Management of Lung Cancer Invading the Superior Sulcus.
    Kratz JR, Woodard G, Jablons DM| | View in PubMed
  54. Mobile Genome Express (MGE): A comprehensive automatic genetic analyses pipeline with a mobile device.
    Yoon JH, Kim TW, Mendez P, Jablons DM, Kim IJ| | View in PubMed
  55. YAP1 regulates ABCG2 and cancer cell side population in human lung cancer cells.
    Dai Y, Liu S, Zhang WQ, Yang YL, Hang P, Wang H, Cheng L, Hsu PC, Wang YC, Xu Z, Jablons DM, You L| | View in PubMed
  56. Gli promotes epithelial-mesenchymal transition in human lung adenocarcinomas.
    Li H, Yue D, Jin JQ, Woodard GA, Tolani B, Luh TM, Giroux-Leprieur E, Mo M, Chen Z, Che J, Zhang Z, Zhou Y, Wang L, Hao X, Jablons D, Wang C, He B| | View in PubMed
  57. FAIM2, as a novel diagnostic maker and a potential therapeutic target for small-cell lung cancer and atypical carcinoid.
    Kang HC, Kim JI, Chang HK, Woodard G, Choi YS, Ku JL, Jablons DM, Kim IJ| | View in PubMed
  58. Hybrid minimally invasive Ivor Lewis esophagectomy after neoadjuvant chemoradiation yields excellent long-term survival outcomes with minimal morbidity.
    Woodard GA, Crockard JC, Clary-Macy C, Zoon-Besselink CT, Jones K, Korn WM, Ko AH, Gottschalk AR, Rogers SJ, Jablons DM| | View in PubMed
  59. Development of a robust DNA quality and quantity assessment qPCR assay for targeted next-generation sequencing library preparation.
    Dang J, Mendez P, Lee S, Kim JW, Yoon JH, Kim TW, Sailey CJ, Jablons DM, Kim IJ| | View in PubMed
  60. YAP promotes erlotinib resistance in human non-small cell lung cancer cells.
    Hsu PC, You B, Yang YL, Zhang WQ, Wang YC, Xu Z, Dai Y, Liu S, Yang CT, Li H, Hu B, Jablons DM, You L| | View in PubMed
  61. Spotlight on afatinib and its potential in the treatment of squamous cell lung cancer: the evidence so far.
    Xu Y, Ding VW, Zhang H, Zhang X, Jablons D, He B| | View in PubMed
  62. Comprehensive evaluation and validation of targeted next-generation sequencing performance in two clinical laboratories.
    Mendez P, Dang J, Kim JW, Lee S, Yoon JH, Kim T, Sailey CJ, Jablons DM, Kim IJ| | View in PubMed
  63. Knockdown of cullin 4A inhibits growth and increases chemosensitivity in lung cancer cells.
    Hung MS, Chen IC, You L, Jablons DM, Li YC, Mao JH, Xu Z, Lung JH, Yang CT, Liu ST| | View in PubMed
  64. SULF2 Expression Is a Potential Diagnostic and Prognostic Marker in Lung Cancer.
    Lui NS, Yang YW, van Zante A, Buchanan P, Jablons DM, Lemjabbar-Alaoui H| | View in PubMed
  65. Whole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomas.
    Kang HC, Kim HK, Lee S, Mendez P, Kim JW, Woodard G, Yoon JH, Jen KY, Fang LT, Jones K, Jablons DM, Kim IJ| | View in PubMed
  66. Lung Cancer Staging and Prognosis.
    Woodard GA, Jones KD, Jablons DM| | View in PubMed
  67. Knockdown of Cul4A increases chemosensitivity to gemcitabine through upregulation of TGFBI in lung cancer cells.
    Hung MS, Chen IC, You L, Jablons DM, Li YC, Mao JH, Xu Z, Hsieh MJ, Lin YC, Yang CT, Liu ST, Tsai YH| | View in PubMed
  68. Cul4A overexpression associated with Gli1 expression in malignant pleural mesothelioma.
    Yang YL, Ni J, Hsu PC, Mao JH, Hsieh D, Xu A, Chan G, Au A, Xu Z, Jablons DM, You L| | View in PubMed
  69. EMX2 Is a Predictive Marker for Adjuvant Chemotherapy in Lung Squamous Cell Carcinomas.
    Yue D, Li H, Che J, Zhang Y, Tolani B, Mo M, Zhang H, Zheng Q, Yang Y, Cheng R, Jin JQ, Luh TW, Yang C, Tseng HH, Giroux-Leprieur E, Woodard GA, Hao X, Wang C, Jablons DM, He B| | View in PubMed
  70. Operative and Perioperative Pulmonary Emboli.
    Cox JC, Jablons DM| | View in PubMed
  71. Analysis of lung tumor initiation and progression in transgenic mice for Cre-inducible overexpression of Cul4A gene.
    Wang Y, Xu Z, Mao JH, Hung MS, Hsieh D, Au A, Jablons DM, You L| | View in PubMed
  72. PR-Set7 is Degraded in a Conditional Cul4A Transgenic Mouse Model of Lung Cancer.
    Wang Y, Xu Z, Mao JH, Hsieh D, Au A, Jablons DM, Li H, You L| | View in PubMed
  73. Transforming Growth Factor-β and Interleukin-1β Signaling Pathways Converge on the Chemokine CCL20 Promoter.
    Brand OJ, Somanath S, Moermans C, Yanagisawa H, Hashimoto M, Cambier S, Markovics J, Bondesson AJ, Hill A, Jablons D, Wolters P, Lou J, Marks JD, Baron JL, Nishimura SL| | View in PubMed
  74. NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer.
    Blakely CM, Pazarentzos E, Olivas V, Asthana S, Yan JJ, Tan I, Hrustanovic G, Chan E, Lin L, Neel DS, Newton W, Bobb KL, Fouts TR, Meshulam J, Gubens MA, Jablons DM, Johnson JR, Bandyopadhyay S, Krogan NJ, Bivona TG| | View in PubMed
  75. Genetic variation in the functional ENG allele inherited from the non-affected parent associates with presence of pulmonary arteriovenous malformation in hereditary hemorrhagic telangiectasia 1 (HHT1) and may influence expression of PTPN14.
    Letteboer TG, Benzinou M, Merrick CB, Quigley DA, Zhau K, Kim IJ, To MD, Jablons DM, van Amstel JK, Westermann CJ, Giraud S, Dupuis-Girod S, Lesca G, Berg JH, Balmain A, Akhurst RJ| | View in PubMed
  76. Inhibition of ERK1/2 down-regulates the Hippo/YAP signaling pathway in human NSCLC cells.
    You B, Yang YL, Xu Z, Dai Y, Liu S, Mao JH, Tetsu O, Li H, Jablons DM, You L| | View in PubMed
  77. Wnt7A is a putative prognostic and chemosensitivity marker in human malignant pleural mesothelioma.
    Hirata T, Zheng Q, Chen Z, Kinoshita H, Okamoto J, Kratz J, Li H, Lui N, Do H, Cheng T, Tseng HH, Koizumi K, Shimizu K, Zhou HM, Jablons D, He B| | View in PubMed
  78. The Latest in Surgical Management of Stage IIIA Non-Small Cell Lung Cancer: Video-Assisted Thoracic Surgery and Tumor Molecular Profiling.
    Woodard GA, Jablons DM| | View in PubMed
  79. CK2α, over-expressed in human malignant pleural mesothelioma, regulates the Hedgehog signaling pathway in mesothelioma cells.
    Zhang S, Yang YL, Wang Y, You B, Dai Y, Chan G, Hsieh D, Kim IJ, Fang LT, Au A, Stoppler HJ, Xu Z, Jablons DM, You L| | View in PubMed
  80. Measurement of genome-wide DNA methylation predicts survival benefits from chemotherapy in non-small cell lung cancer.
    Mo ML, Ma J, Chen Z, Wei B, Li H, Zhou Y, Shi H, Tolani B, Jin JQ, Tseng HH, Shen D, Zhan Y, Li J, Jablons DM, Zhang RQ, Guo Y, He B, Zhou HM| | View in PubMed
  81. Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma.
    Capelletti M, Dodge ME, Ercan D, Hammerman PS, Park SI, Kim J, Sasaki H, Jablons DM, Lipson D, Young L, Stephens PJ, Miller VA, Lindeman NI, Munir KJ, Richards WG, Jänne PA| | View in PubMed
  82. Prognostic molecular assay might improve identification of patients at risk for recurrence in early-stage non-small-cell lung cancer.
    Woodard GA, Gubens MA, Jahan TM, Jones KD, Kukreja J, Theodore PR, Cardozo S, Jew G, Clary-Macy C, Jablons DM, Mann MJ| | View in PubMed
  83. An alternative way to initiate Notch1 signaling in non-small cell lung cancer.
    Yang YL, Jablons D, You L| | View in PubMed
  84. Divergent management strategies for typical versus atypical carcinoid tumors of the thoracic cavity.
    Okoye CC, Jablons DM, Jahan TM, Kukreja J, Cardozo S, Yom SS| | View in PubMed
  85. The homeobox gene EMX2 is a prognostic and predictive marker in malignant pleural mesothelioma.
    Giroux Leprieur E, Hirata T, Mo M, Chen Z, Okamoto J, Clement G, Li H, Wislez M, Jablons DM, He B| | View in PubMed
  86. Selective targeting of TGF-β activation to treat fibroinflammatory airway disease.
    Minagawa S, Lou J, Seed RI, Cormier A, Wu S, Cheng Y, Murray L, Tsui P, Connor J, Herbst R, Govaerts C, Barker T, Cambier S, Yanagisawa H, Goodsell A, Hashimoto M, Brand OJ, Cheng R, Ma R, McKnelly KJ, Wen W, Hill A, Jablons D, Wolters P, Kitamura H, Araya J, Barczak AJ, Erle DJ, Reichardt LF, Marks JD, Baron JL, Nishimura SL| | View in PubMed
  87. Lung tumourigenesis in a conditional Cul4A transgenic mouse model.
    Yang YL, Hung MS, Wang Y, Ni J, Mao JH, Hsieh D, Au A, Kumar A, Quigley D, Fang LT, Yeh CC, Xu Z, Jablons DM, You L| | View in PubMed
  88. Hedgehog/Gli promotes epithelial-mesenchymal transition in lung squamous cell carcinomas.
    Yue D, Li H, Che J, Zhang Y, Tseng HH, Jin JQ, Luh TM, Giroux-Leprieur E, Mo M, Zheng Q, Shi H, Zhang H, Hao X, Wang C, Jablons DM, He B| | View in PubMed
  89. A positive feedback between p53 and miR-34 miRNAs mediates tumor suppression.
    Okada N, Lin CP, Ribeiro MC, Biton A, Lai G, He X, Bu P, Vogel H, Jablons DM, Keller AC, Wilkinson JE, He B, Speed TP, He L| | View in PubMed
  90. Aggressive and minimally invasive surgery for pulmonary metastasis of sarcoma.
    Reza J, Sammann A, Jin C, Horvai A, Hudnall M, Jablons DM, Jahan T, Kornak J, Mann MJ| | View in PubMed
  91. Comprehensive genomic analyses of a metastatic colon cancer to the lung by whole exome sequencing and gene expression analysis.
    Fang LT, Lee S, Choi H, Kim HK, Jew G, Kang HC, Chen L, Jablons D, Kim IJ| | View in PubMed
  92. VATS lobectomy facilitates the delivery of adjuvant docetaxel-carboplatin chemotherapy in patients with non-small cell lung cancer.
    Zhi X, Gao W, Han B, Yang Y, Li H, Liu D, Wang C, Min G, Long H, Rigas JR, Carey M, Jahan T, Sammann A, Reza J, Wang D, Mann MJ, Jablons DM, He J, China Clinical Trials Consortium| | View in PubMed
  93. Hematein, a casein kinase II inhibitor, inhibits lung cancer tumor growth in a murine xenograft model.
    Hung MS, Xu Z, Chen Y, Smith E, Mao JH, Hsieh D, Lin YC, Yang CT, Jablons DM, You L| | View in PubMed
  94. Desmoplastic fibroma of the spine causing severe mediastinal compression and brachial plexus encasement: report of 2 cases.
    Lau D, Yarlagadda J, Jahan T, Jablons D, Chou D| | View in PubMed
  95. Down-regulation of SIX3 is associated with clinical outcome in lung adenocarcinoma.
    Mo ML, Okamoto J, Chen Z, Hirata T, Mikami I, Bosco-Clément G, Li H, Zhou HM, Jablons DM, He B| | View in PubMed
  96. Tumor-infiltrating regulatory T cells inhibit endogenous cytotoxic T cell responses to lung adenocarcinoma.
    Ganesan AP, Johansson M, Ruffell B, Yagui-Beltrán A, Beltran A, Lau J, Jablons DM, Coussens LM| | View in PubMed
  97. Coumestrol from the national cancer Institute's natural product library is a novel inhibitor of protein kinase CK2.
    Liu S, Hsieh D, Yang YL, Xu Z, Peto C, Jablons DM, You L| | View in PubMed
  98. Frizzled-8 receptor is activated by the Wnt-2 ligand in non-small cell lung cancer.
    Bravo DT, Yang YL, Kuchenbecker K, Hung MS, Xu Z, Jablons DM, You L| | View in PubMed
  99. Analytical validation of a practical molecular assay prognostic of survival in nonsquamous non-small cell lung cancer.
    Kratz JR, Tham PT, Mulvihill MS, Ziaei F, Ray MR, Hurst JW, Segal MR, Berryman DM, Chu W, He B, Jablons DM, Mann MJ| | View in PubMed
  100. International trial of adjuvant therapy in high risk stage I non-squamous cell carcinoma identified by a 14-gene prognostic signature.
    Kratz JR, Mann MJ, Jablons DM| | View in PubMed
  101. Detection of E2A-PBX1 fusion transcripts in human non-small-cell lung cancer.
    Mo ML, Chen Z, Zhou HM, Li H, Hirata T, Jablons DM, He B| | View in PubMed
  102. Targeting Gli transcription activation by small molecule suppresses tumor growth.
    Bosco-Clément G, Zhang F, Chen Z, Zhou HM, Li H, Mikami I, Hirata T, Yagui-Beltran A, Lui N, Do HT, Cheng T, Tseng HH, Choi H, Fang LT, Kim IJ, Yue D, Wang C, Zheng Q, Fujii N, Mann M, Jablons DM, He B| | View in PubMed
  103. Inhibition of CK2α down-regulates Notch1 signalling in lung cancer cells.
    Zhang S, Long H, Yang YL, Wang Y, Hsieh D, Li W, Au A, Stoppler HJ, Xu Z, Jablons DM, You L| | View in PubMed
  104. Gli as a novel therapeutic target in malignant pleural mesothelioma.
    Li H, Lui N, Cheng T, Tseng HH, Yue D, Giroux-Leprieur E, Do HT, Sheng Q, Jin JQ, Luh TW, Jablons DM, He B| | View in PubMed
  105. Prognostic assay in small, node-negative non-small cell lung cancer--reply.
    Mann MJ, Jablons DM, Kratz JR| | View in PubMed
  106. SMO expression level correlates with overall survival in patients with malignant pleural mesothelioma.
    Zhang Y, He J, Zhang F, Li H, Yue D, Wang C, Jablons DM, He B, Lui N| | View in PubMed
  107. Molecular prognostication of non-small cell lung cancer.
    Tsao MS, Jablons DM| | View in PubMed
  108. Rewiring of human lung cell lineage and mitotic networks in lung adenocarcinomas.
    Kim IJ, Quigley D, To MD, Pham P, Lin K, Jo B, Jen KY, Raz D, Kim J, Mao JH, Jablons D, Balmain A| | View in PubMed
  109. Identification of pY654-β-catenin as a critical co-factor in hypoxia-inducible factor-1α signaling and tumor responses to hypoxia.
    Xi Y, Wei Y, Sennino B, Ulsamer A, Kwan I, Brumwell AN, Tan K, Aghi MK, McDonald DM, Jablons DM, Chapman HA| | View in PubMed
  110. SULF2 expression by immunohistochemistry and overall survival in oesophageal cancer: a cohort study.
    Lui NS, van Zante A, Rosen SD, Jablons DM, Lemjabbar-Alaoui H| | View in PubMed
  111. The role of stem cells in airway repair: implications for the origins of lung cancer.
    Mulvihill MS, Kratz JR, Pham P, Jablons DM, He B| | View in PubMed
  112. A prognostic assay to identify patients at high risk of mortality despite small, node-negative lung tumors.
    Kratz JR, Van den Eeden SK, He J, Jablons DM, Mann MJ| | View in PubMed
  113. Gremlin is overexpressed in lung adenocarcinoma and increases cell growth and proliferation in normal lung cells.
    Mulvihill MS, Kwon YW, Lee S, Fang LT, Choi H, Ray R, Kang HC, Mao JH, Jablons D, Kim IJ| | View in PubMed
  114. A somatic TSHR mutation in a patient with lung adenocarcinoma with bronchioloalveolar carcinoma, coronary artery disease and severe chronic obstructive pulmonary disease.
    Kim JW, Lee S, Lui N, Choi H, Mulvihill M, Fang LT, Kang HC, Kwon YW, Jablons D, Kim IJ| | View in PubMed
  115. Inhibition of CK2α down-regulates Hedgehog/Gli signaling leading to a reduction of a stem-like side population in human lung cancer cells.
    Zhang S, Wang Y, Mao JH, Hsieh D, Kim IJ, Hu LM, Xu Z, Long H, Jablons DM, You L| | View in PubMed
  116. The expression of Dishevelled-3 and glutamine metabolism in malignant pleural mesothelioma.
    Li T, Hou SC, Mao JH, Wang YC, Lu XD, Tan JL, You B, Liu YP, Ni J, Au A, Jablons DM, Xu Z, You L| | View in PubMed
  117. One size does not fit all lung cancer patients.
    Yom SS, Chen CP, Jahan TM, Jablons DM| | View in PubMed
  118. Development of a rapid and practical mutation screening assay for human lung adenocarcinoma.
    Choi H, Kratz J, Pham P, Lee S, Ray R, Kwon YW, Mao JH, Kang HC, Jablons D, Kim IJ| | View in PubMed
  119. A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies.
    Kratz JR, He J, Van Den Eeden SK, Zhu ZH, Gao W, Pham PT, Mulvihill MS, Ziaei F, Zhang H, Su B, Zhi X, Quesenberry CP, Habel LA, Deng Q, Wang Z, Zhou J, Li H, Huang MC, Yeh CC, Segal MR, Ray MR, Jones KD, Raz DJ, Xu Z, Jahan TM, Berryman D, He B, Mann MJ, Jablons DM| | View in PubMed
  120. Implications of delayed initiation of radiotherapy: accelerated repopulation after induction chemotherapy for stage III non-small cell lung cancer.
    Chen CP, Weinberg VK, Jahan TM, Jablons DM, Yom SS| | View in PubMed
  121. Interleukin-1beta induces increased transcriptional activation of the transforming growth factor-beta-activating integrin subunit beta8 through altering chromatin architecture.
    Markovics JA, Araya J, Cambier S, Somanath S, Gline S, Jablons D, Hill A, Wolters PJ, Nishimura SL| | View in PubMed
  122. Wnt and hedgehog gene pathway expression in serous ovarian cancer.
    Schmid S, Bieber M, Zhang F, Zhang M, He B, Jablons D, Teng NN| | View in PubMed
  123. The Bcl-2 repertoire of mesothelioma spheroids underlies acquired apoptotic multicellular resistance.
    Barbone D, Ryan JA, Kolhatkar N, Chacko AD, Jablons DM, Sugarbaker DJ, Bueno R, Letai AG, Coussens LM, Fennell DA, Broaddus VC| | View in PubMed
  124. Mouse and human lung fibroblasts regulate dendritic cell trafficking, airway inflammation, and fibrosis through integrin αvβ8-mediated activation of TGF-β.
    Kitamura H, Cambier S, Somanath S, Barker T, Minagawa S, Markovics J, Goodsell A, Publicover J, Reichardt L, Jablons D, Wolters P, Hill A, Marks JD, Lou J, Pittet JF, Gauldie J, Baron JL, Nishimura SL| | View in PubMed
  125. Downregulation of EMX2 is associated with clinical outcomes in lung adenocarcinoma patients.
    Okamoto J, Kratz JR, Hirata T, Mikami I, Raz D, Segal M, Chen Z, Zhou HM, Pham P, Li H, Yagui-Beltran A, Beltran A, Ray MR, Koizumi K, Shimizu K, Jablons D, He B| | View in PubMed
  126. Transgenic mice for cre-inducible overexpression of the Cul4A gene.
    Li T, Hung MS, Wang Y, Mao JH, Tan JL, Jahan K, Roos H, Xu Z, Jablons DM, You L| | View in PubMed
  127. Cul4A is an oncogene in malignant pleural mesothelioma.
    Hung MS, Mao JH, Xu Z, Yang CT, Yu JS, Harvard C, Lin YC, Bravo DT, Jablons DM, You L| | View in PubMed
  128. The expression of CXCR4, CXCL12 and CXCR7 in malignant pleural mesothelioma.
    Li T, Li H, Wang Y, Harvard C, Tan JL, Au A, Xu Z, Jablons DM, You L| | View in PubMed
  129. Adenovirus-mediated SOCS3 gene transfer inhibits the growth and enhances the radiosensitivity of human non-small cell lung cancer cells.
    Lin YC, Lin CK, Tsai YH, Weng HH, Li YC, You L, Chen JK, Jablons DM, Yang CT| | View in PubMed
  130. Inhibition of activated phosphatidylinositol 3-kinase/AKT pathway in malignant pleural mesothelioma leads to G1 cell cycle arrest.
    Mikami I, Zhang F, Hirata T, Okamoto J, Koizumi K, Shimizu K, Jablons D, He B| | View in PubMed
  131. Lung cancer therapeutics that target signaling pathways: an update.
    Ray MR, Jablons D, He B| | View in PubMed
  132. EMX2 is epigenetically silenced and suppresses growth in human lung cancer.
    Okamoto J, Hirata T, Chen Z, Zhou HM, Mikami I, Li H, Yagui-Beltran A, Beltran A, Johansson M, Coussens LM, Clement G, Shi Y, Zhang F, Koizumi K, Shimizu K, Jablons D, He B| | View in PubMed
  133. Functional polymorphism of the CK2alpha intronless gene plays oncogenic roles in lung cancer.
    Hung MS, Lin YC, Mao JH, Kim IJ, Xu Z, Yang CT, Jablons DM, You L| | View in PubMed
  134. Transcription of the transforming growth factor beta activating integrin beta8 subunit is regulated by SP3, AP-1, and the p38 pathway.
    Markovics JA, Araya J, Cambier S, Jablons D, Hill A, Wolters PJ, Nishimura SL| | View in PubMed
  135. Cancer stem cells in lung tumorigenesis.
    Kratz JR, Yagui-Beltrán A, Jablons DM| | View in PubMed
  136. Lack of NKX2.2 expression in bronchopulmonary typical carcinoid tumors: implications for patients with neuroendocrine tumor metastases and unknown primary site.
    Wang YC, Iezza G, Zuraek MB, Jablons DM, Theodore PR, Bergsland EK, Donner DB, Warren RS, Nakakura EK| | View in PubMed
  137. Organic cation transporters modulate the uptake and cytotoxicity of picoplatin, a third-generation platinum analogue.
    More SS, Li S, Yee SW, Chen L, Xu Z, Jablons DM, Giacomini KM| | View in PubMed
  138. A safe and reproducible anastomotic technique for minimally invasive Ivor Lewis oesophagectomy: the circular-stapled anastomosis with the trans-oral anvil.
    Campos GM, Jablons D, Brown LM, Ramirez RM, Rabl C, Theodore P| | View in PubMed
  139. Procaine and procainamide inhibit the Wnt canonical pathway by promoter demethylation of WIF-1 in lung cancer cells.
    Gao Z, Xu Z, Hung MS, Lin YC, Wang T, Gong M, Zhi X, Jablons DM, You L| | View in PubMed
  140. Discovery of molecular subtypes in leiomyosarcoma through integrative molecular profiling.
    Beck AH, Lee CH, Witten DM, Gleason BC, Edris B, Espinosa I, Zhu S, Li R, Montgomery KD, Marinelli RJ, Tibshirani R, Hastie T, Jablons DM, Rubin BP, Fletcher CD, West RB, van de Rijn M| | View in PubMed
  141. Sulf-2, a heparan sulfate endosulfatase, promotes human lung carcinogenesis.
    Lemjabbar-Alaoui H, van Zante A, Singer MS, Xue Q, Wang YQ, Tsay D, He B, Jablons DM, Rosen SD| | View in PubMed
  142. A translational approach to lung cancer research: From EGFRs to Wnt and cancer stem cells.
    Yagui-Beltrán A, Jablons DM| | View in PubMed
  143. Identification of hematein as a novel inhibitor of protein kinase CK2 from a natural product library.
    Hung MS, Xu Z, Lin YC, Mao JH, Yang CT, Chang PJ, Jablons DM, You L| | View in PubMed
  144. Genomic prognostic models in early-stage lung cancer.
    Kratz JR, Jablons DM| | View in PubMed
  145. A multi-marker assay to distinguish malignant melanomas from benign nevi.
    Kashani-Sabet M, Rangel J, Torabian S, Nosrati M, Simko J, Jablons DM, Moore DH, Haqq C, Miller JR, Sagebiel RW| | View in PubMed
  146. Respiratory Homeostasis and Exploitation of the Immune System for Lung Cancer Vaccines.
    Yagui-Beltrán A, Coussens LM, Jablons DM| | View in PubMed
  147. Epidemiology of non-small cell lung cancer in Asian Americans: incidence patterns among six subgroups by nativity.
    Raz DJ, Gomez SL, Chang ET, Kim JY, Keegan TH, Pham J, Kukreja J, Hiatt RA, Jablons DM| | View in PubMed
  148. The role of cancer stem cells in neoplasia of the lung: past, present and future.
    Yagui-Beltrán A, He B, Jablons DM| | View in PubMed
  149. Inhibition of Hsp90 leads to cell cycle arrest and apoptosis in human malignant pleural mesothelioma.
    Okamoto J, Mikami I, Tominaga Y, Kuchenbecker KM, Lin YC, Bravo DT, Clement G, Yagui-Beltran A, Ray MR, Koizumi K, He B, Jablons DM| | View in PubMed
  150. A multigene assay is prognostic of survival in patients with early-stage lung adenocarcinoma.
    Raz DJ, Ray MR, Kim JY, He B, Taron M, Skrzypski M, Segal M, Gandara DR, Rosell R, Jablons DM| | View in PubMed
  151. Three-gene expression signature predicts survival in early-stage squamous cell carcinoma of the lung.
    Skrzypski M, Jassem E, Taron M, Sanchez JJ, Mendez P, Rzyman W, Gulida G, Raz D, Jablons D, Provencio M, Massuti B, Chaib I, Perez-Roca L, Jassem J, Rosell R| | View in PubMed
  152. Nasopharyngeal carcinoma--review of the molecular mechanisms of tumorigenesis.
    Chou J, Lin YC, Kim J, You L, Xu Z, He B, Jablons DM| | View in PubMed
  153. Evaluation of a chemical library of small-molecule Dishevelled antagonists that suppress tumor growth by down-regulating T-cell factor-mediated transcription.
    You L, Xu Z, Punchihewa C, Jablons DM, Fujii N| | View in PubMed
  154. mTOR mediates survival signals in malignant mesothelioma grown as tumor fragment spheroids.
    Wilson SM, Barbone D, Yang TM, Jablons DM, Bueno R, Sugarbaker DJ, Nishimura SL, Gordon GJ, Broaddus VC| | View in PubMed
  155. Adjuvant treatment of stage IB NSCLC: the problem of stage subset heterogeneity.
    Calhoun R, Jablons D, Lau D, Gandara DR| | View in PubMed
  156. Translational research in glioblastoma multiforme: molecular criteria for patient selection.
    Rosell R, de Las Peñas R, Balaña C, Santarpia M, Salazar F, de Aguirre I, Reguart N, Villa S, Wei J, Ramirez JL, Molina MA, Ramon y Cajal S, Jablons D, Taron M| | View in PubMed
  157. Unmet need in lung cancer: can vaccines bridge the gap?
    Kim J, Raz D, Jablons D| | View in PubMed
  158. Pharmacogenomic approaches to individualizing chemotherapy for non-small-cell lung cancer: current status and new directions.
    Gautschi O, Mack PC, Davies AM, Jablons DM, Rosell R, Gandara DR| | View in PubMed
  159. Optimal surgical management of Stage I non-small-cell lung cancer in an increasingly aging population: challenges and recent progress.
    Yagui-Beltrán A, Jablons DM| | View in PubMed
  160. Epigenetic regulation of RhoB loss of expression in lung cancer.
    Mazières J, Tovar D, He B, Nieto-Acosta J, Marty-Detraves C, Clanet C, Pradines A, Jablons D, Favre G| | View in PubMed
  161. Epigenetic alteration of the Wnt inhibitory factor-1 promoter occurs early in the carcinogenesis of Barrett's esophagus.
    Clément G, Guilleret I, He B, Yagui-Beltrán A, Lin YC, You L, Xu Z, Shi Y, Okamoto J, Benhattar J, Jablons D| | View in PubMed
  162. Squamous metaplasia amplifies pathologic epithelial-mesenchymal interactions in COPD patients.
    Araya J, Cambier S, Markovics JA, Wolters P, Jablons D, Hill A, Finkbeiner W, Jones K, Broaddus VC, Sheppard D, Barzcak A, Xiao Y, Erle DJ, Nishimura SL| | View in PubMed
  163. Targeting the Wnt signaling pathway with dishevelled and cisplatin synergistically suppresses mesothelioma cell growth.
    Uematsu K, Seki N, Seto T, Isoe C, Tsukamoto H, Mikami I, You L, He B, Xu Z, Jablons DM, Eguchi K| | View in PubMed
  164. Inhibition of Wnt-2 and galectin-3 synergistically destabilizes beta-catenin and induces apoptosis in human colorectal cancer cells.
    Shi Y, He B, Kuchenbecker KM, You L, Xu Z, Mikami I, Yagui-Beltran A, Clement G, Lin YC, Okamoto J, Bravo DT, Jablons DM| | View in PubMed
  165. Roles of secreted frizzled-related proteins in cancer.
    Shi Y, He B, You L, Jablons DM| | View in PubMed
  166. Adjuvant chemotherapy of stage I non-small cell lung cancer in North America.
    Gandara DR, Wakelee H, Calhoun R, Jablons D| | View in PubMed
  167. Diagnosis and treatment of bronchioloalveolar carcinoma.
    Raz DJ, Kim JY, Jablons DM| | View in PubMed
  168. Impact of induction treatment on postoperative complications in the treatment of non-small cell lung cancer.
    Brouchet L, Bauvin E, Marcheix B, Bigay-Game L, Renaud C, Berjaud J, Falcoze PE, Venissac N, Raz D, Jablons D, Mazières J, Dahan M| | View in PubMed
  169. EGFR expression and mutational analysis as a predictive test.
    Raz DJ, Jablons DM| | View in PubMed
  170. Natural history of stage I non-small cell lung cancer: implications for early detection.
    Raz DJ, Zell JA, Ou SH, Gandara DR, Anton-Culver H, Jablons DM| | View in PubMed
  171. Risk of cerebral metastases and neurological death after pathological complete response to neoadjuvant therapy for locally advanced nonsmall-cell lung cancer: clinical implications for the subsequent management of the brain.
    Chen AM, Jahan TM, Jablons DM, Garcia J, Larson DA| | View in PubMed
  172. Update on the molecular biology of malignant mesothelioma.
    Lee AY, Raz DJ, He B, Jablons DM| | View in PubMed
  173. Five-gene signature in non-small-cell lung cancer.
    Raz DJ, Jablons DM| | View in PubMed
  174. Wnt inhibitory factor-1 gene transfer inhibits melanoma cell growth.
    Lin YC, You L, Xu Z, He B, Yang CT, Chen JK, Mikami I, Clément G, Shi Y, Kuchenbecker K, Okamoto J, Kashani-Sabet M, Jablons DM| | View in PubMed
  175. Targeting the Wnt signaling pathway to treat Barrett's esophagus.
    Clément G, Jablons DM, Benhattar J| | View in PubMed
  176. Wnt inhibitory factor inhibits lung cancer cell growth.
    Kim J, You L, Xu Z, Kuchenbecker K, Raz D, He B, Jablons D| | View in PubMed
  177. Clinical characteristics and survival of patients with surgically resected, incidentally detected lung cancer.
    Raz DJ, Glidden DV, Odisho AY, Jablons DM| | View in PubMed
  178. An antagonist of dishevelled protein-protein interaction suppresses beta-catenin-dependent tumor cell growth.
    Fujii N, You L, Xu Z, Uematsu K, Shan J, He B, Mikami I, Edmondson LR, Neale G, Zheng J, Guy RK, Jablons DM| | View in PubMed
  179. Patterns of metastasis in human solid cancers.
    Leong SP, Cady B, Jablons DM, Garcia-Aguilar J, Reintgen D, Werner JA, Kitagawa Y| | View in PubMed
  180. Stathmin is overexpressed in malignant mesothelioma.
    Kim JY, Harvard C, You L, Xu Z, Kuchenbecker K, Baehner R, Jablons D| | View in PubMed
  181. Misclassification of bronchioloalveolar carcinoma with cytologic diagnosis of lung cancer.
    Raz DJ, Zell JA, Karnezis AN, Odisho A, Ignatius Ou SH, Anton-Culver H, Jablons DM| | View in PubMed
  182. Novel therapies targeting signaling pathways in lung cancer.
    Yagui-Beltrán A, He B, Raz D, Kim J, Jablons DM| | View in PubMed
  183. Tumor fluoro-2-deoxy-D-glucose avidity on positron emission tomographic scan predicts mortality in patients with early-stage pure and mixed bronchioloalveolar carcinoma.
    Raz DJ, Odisho AY, Franc BL, Jablons DM| | View in PubMed
  184. Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer.
    Zhou BB, Peyton M, He B, Liu C, Girard L, Caudler E, Lo Y, Baribaud F, Mikami I, Reguart N, Yang G, Li Y, Yao W, Vaddi K, Gazdar AF, Friedman SM, Jablons DM, Newton RC, Fridman JS, Minna JD, Scherle PA| | View in PubMed
  185. Current concepts in bronchioloalveolar carcinoma biology.
    Raz DJ, He B, Rosell R, Jablons DM| | View in PubMed
  186. Clinical patterns of metastasis.
    Leong SP, Cady B, Jablons DM, Garcia-Aguilar J, Reintgen D, Jakub J, Pendas S, Duhaime L, Cassell R, Gardner M, Giuliano R, Archie V, Calvin D, Mensha L, Shivers S, Cox C, Werner JA, Kitagawa Y, Kitajima M| | View in PubMed
  187. Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer.
    Nemunaitis J, Jahan T, Ross H, Sterman D, Richards D, Fox B, Jablons D, Aimi J, Lin A, Hege K| | View in PubMed
  188. Bronchioloalveolar carcinoma is not associated with younger age at diagnosis: an analysis of the SEER database.
    Raz DJ, Jablons DM| | View in PubMed
  189. Bronchioloalveolar carcinoma: a review.
    Raz DJ, He B, Rosell R, Jablons DM| | View in PubMed
  190. Wnt inhibitory factor-1, a Wnt antagonist, is silenced by promoter hypermethylation in malignant pleural mesothelioma.
    Batra S, Shi Y, Kuchenbecker KM, He B, Reguart N, Mikami I, You L, Xu Z, Lin YC, Clément G, Jablons DM| | View in PubMed
  191. Future directions in the second-line treatment of non-small cell lung cancer.
    Rosell R, Cecere F, Cognetti F, Cuello M, Sanchez JM, Taron M, Reguart N, Jablons D| | View in PubMed
  192. Wnt signaling activation and WIF-1 silencing in nasopharyngeal cancer cell lines.
    Lin YC, You L, Xu Z, He B, Mikami I, Thung E, Chou J, Kuchenbecker K, Kim J, Raz D, Yang CT, Chen JK, Jablons DM| | View in PubMed
  193. Wnt signaling in stem cells and lung cancer.
    He B, Jablons DM| | View in PubMed
  194. Wnt-1 signal as a potential cancer therapeutic target.
    You L, Kim J, He B, Xu Z, McCormick F, Jablons DM| | View in PubMed
  195. The role of Wnt signaling in cancer and stem cells.
    Reguart N, He B, Taron M, You L, Jablons DM, Rosell R| | View in PubMed
  196. Wnt2 as a new therapeutic target in malignant pleural mesothelioma.
    Mazieres J, You L, He B, Xu Z, Twogood S, Lee AY, Reguart N, Batra S, Mikami I, Jablons DM| | View in PubMed
  197. A novel in vitro model of human mesothelioma for studying tumor biology and apoptotic resistance.
    Kim KU, Wilson SM, Abayasiriwardana KS, Collins R, Fjellbirkeland L, Xu Z, Jablons DM, Nishimura SL, Broaddus VC| | View in PubMed
  198. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas.
    Taron M, Ichinose Y, Rosell R, Mok T, Massuti B, Zamora L, Mate JL, Manegold C, Ono M, Queralt C, Jahan T, Sanchez JJ, Sanchez-Ronco M, Hsue V, Jablons D, Sanchez JM, Moran T| | View in PubMed
  199. Inhibition of Wnt16 in human acute lymphoblastoid leukemia cells containing the t(1;19) translocation induces apoptosis.
    Mazieres J, You L, He B, Xu Z, Lee AY, Mikami I, McCormick F, Jablons DM| | View in PubMed
  200. Wnt signaling in stem cells and non-small-cell lung cancer.
    He B, Barg RN, You L, Xu Z, Reguart N, Mikami I, Batra S, Rosell R, Jablons DM| | View in PubMed
  201. Efficacy of Wnt-1 monoclonal antibody in sarcoma cells.
    Mikami I, You L, He B, Xu Z, Batra S, Lee AY, Mazieres J, Reguart N, Uematsu K, Koizumi K, Jablons DM| | View in PubMed
  202. Wnt signaling in lung cancer.
    Mazieres J, He B, You L, Xu Z, Jablons DM| | View in PubMed
  203. Blockade of Wnt-1 signaling induces apoptosis in human colorectal cancer cells containing downstream mutations.
    He B, Reguart N, You L, Mazieres J, Xu Z, Lee AY, Mikami I, McCormick F, Jablons DM| | View in PubMed
  204. Unusual thoracic problems in patients with malignancies: case 3. Carcinoid tumor of the thymus.
    Hansen EK, Krieg RM, Azar RJ, Jablons DM, Jahan TM, Zaloudek CJ| | View in PubMed
  205. Changes in radiographic abnormalities in organ donors: associations with lung transplantation.
    McCowin MJ, Hall TS, Babcock WD, Solinger LL, Hall KW, Jablons DM| | View in PubMed
  206. Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion.
    Dresler CM, Olak J, Herndon JE, Richards WG, Scalzetti E, Fleishman SB, Kernstine KH, Demmy T, Jablons DM, Kohman L, Daniel TM, Haasler GB, Sugarbaker DJ, Cooperative Groups Cancer and Leukemia Group B, Eastern Cooperative Oncology Group, North Central Cooperative Oncology Group, Radiation Therapy Oncology Group| | View in PubMed
  207. Secreted frizzled-related protein 4 is silenced by hypermethylation and induces apoptosis in beta-catenin-deficient human mesothelioma cells.
    He B, Lee AY, Dadfarmay S, You L, Xu Z, Reguart N, Mazieres J, Mikami I, McCormick F, Jablons DM| | View in PubMed
  208. Salmonella infection in an anterior mediastinal mass.
    Carter YM, Shagrun L, Klein H, Katz J, Jablons DM| | View in PubMed
  209. Dickkopf-1 antagonizes Wnt signaling independent of beta-catenin in human mesothelioma.
    Lee AY, He B, You L, Xu Z, Mazieres J, Reguart N, Mikami I, Batra S, Jablons DM| | View in PubMed
  210. Cloning and characterization of the promoter of human Wnt inhibitory factor-1.
    Reguart N, He B, Xu Z, You L, Lee AY, Mazieres J, Mikami I, Batra S, Rosell R, McCormick F, Jablons DM| | View in PubMed
  211. Expression of the secreted frizzled-related protein gene family is downregulated in human mesothelioma.
    Lee AY, He B, You L, Dadfarmay S, Xu Z, Mazieres J, Mikami I, McCormick F, Jablons DM| | View in PubMed
  212. Inhibition of Wnt-2-mediated signaling induces programmed cell death in non-small-cell lung cancer cells.
    You L, He B, Xu Z, Uematsu K, Mazieres J, Mikami I, Reguart N, Moody TW, Kitajewski J, McCormick F, Jablons DM| | View in PubMed
  213. An anti-Wnt-2 monoclonal antibody induces apoptosis in malignant melanoma cells and inhibits tumor growth.
    You L, He B, Xu Z, Uematsu K, Mazieres J, Fujii N, Mikami I, Reguart N, McIntosh JK, Kashani-Sabet M, McCormick F, Jablons DM| | View in PubMed
  214. Interleukin-4 receptor cytotoxin as therapy for human malignant pleural mesothelioma xenografts.
    Beseth BD, Cameron RB, Leland P, You L, Varricchio F, Kreitman RJ, Maki RA, Jablons DM, Husain SR, Puri RK| | View in PubMed
  215. Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer.
    Mazieres J, He B, You L, Xu Z, Lee AY, Mikami I, Reguart N, Rosell R, McCormick F, Jablons DM| | View in PubMed
  216. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.
    Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF, Gaudreault J, Damico LA, Holmgren E, Kabbinavar F| | View in PubMed
  217. Inhibition of Wnt-1 signaling induces apoptosis in beta-catenin-deficient mesothelioma cells.
    You L, He B, Uematsu K, Xu Z, Mazieres J, Lee A, McCormick F, Jablons DM| | View in PubMed
  218. Activity of the suppressor of cytokine signaling-3 promoter in human non-small-cell lung cancer.
    He B, You L, Xu Z, Mazieres J, Lee AY, Jablons DM| | View in PubMed
  219. Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer.
    Nemunaitis J, Sterman D, Jablons D, Smith JW, Fox B, Maples P, Hamilton S, Borellini F, Lin A, Morali S, Hege K| | View in PubMed
  220. Isolated pulmonary arteriovenous malformations requiring anatomic resection.
    Mann MJ, Kramer MJ, Hall TS, Anastassiou P, Katz J, Golden J, Jones K, Jablons DM| | View in PubMed
  221. A monoclonal antibody against Wnt-1 induces apoptosis in human cancer cells.
    He B, You L, Uematsu K, Xu Z, Lee AY, Matsangou M, McCormick F, Jablons DM| | View in PubMed
  222. Future directions: oncolytic viruses.
    You L, He B, Xu Z, McCormick F, Jablons DM| | View in PubMed
  223. Malignant pleural mesothelioma: evaluation with CT, MR imaging, and PET.
    Wang ZJ, Reddy GP, Gotway MB, Higgins CB, Jablons DM, Ramaswamy M, Hawkins RA, Webb WR| | View in PubMed
  224. Mechanisms of and potential treatment strategies for metastatic disease in non-small cell lung cancer.
    Maslyar DJ, Jahan TM, Jablons DM| | View in PubMed
  225. Retrocardiac parathyroid tumor: a rare mediastinal site.
    Corvera CU, Jablons D, Morita E, Clark OH| | View in PubMed
  226. SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer.
    He B, You L, Uematsu K, Zang K, Xu Z, Lee AY, Costello JF, McCormick F, Jablons DM| | View in PubMed
  227. Activation of the Wnt pathway in non small cell lung cancer: evidence of dishevelled overexpression.
    Uematsu K, He B, You L, Xu Z, McCormick F, Jablons DM| | View in PubMed
  228. Intraoperative radiation therapy in the multimodality approach to upper aerodigestive tract cancer.
    Carter YM, Jablons DM, DuBois JB, Thomas CR| | View in PubMed
  229. Potential of mobile intraoperative radiotherapy technology.
    Goer DA, Musslewhite CW, Jablons DM| | View in PubMed
  230. 1st International Lung Cancer Conference in Beijing, October 27-30, 2002.
    Jablons DM, Cheng SJ, Carolyn Clary-Macy RN, Hirsch FR| | View in PubMed
  231. Integrin alphavbeta8-mediated activation of transforming growth factor-beta inhibits human airway epithelial proliferation in intact bronchial tissue.
    Fjellbirkeland L, Cambier S, Broaddus VC, Hill A, Brunetta P, Dolganov G, Jablons D, Nishimura SL| | View in PubMed
  232. Wnt pathway activation in mesothelioma: evidence of Dishevelled overexpression and transcriptional activity of beta-catenin.
    Uematsu K, Kanazawa S, You L, He B, Xu Z, Li K, Peterlin BM, McCormick F, Jablons DM| | View in PubMed
  233. c-Kit is not expressed in malignant mesothelioma.
    Horvai AE, Li L, Xu Z, Kramer MJ, Jablons DM, Treseler PA| | View in PubMed
  234. Genomic alterations in human mesothelioma including high resolution mapping of common regions of DNA loss in chromosome arm 6q.
    Jensen RH, Tiirikainen M, You L, Ginzinger D, He B, Uematsu K, Xu Z, Treseler P, McCormick F, Jablons DM| | View in PubMed
  235. Malignant mesothelioma does not demonstrate overexpression or gene amplification despite cytoplasmic immunohistochemical staining for c-Erb-B2.
    Horvai AE, Li L, Xu Z, Kramer MJ, Jablons DM, Treseler PA| | View in PubMed
  236. Cloning and characterization of a functional promoter of the human SOCS-3 gene.
    He B, You L, Uematsu K, Matsangou M, Xu Z, He M, McCormick F, Jablons DM| | View in PubMed
  237. Pericardial retraction sutures facilitate intrapericardial pneumonectomy.
    Brevetti GR, Lin SC, Jablons DM, Napierkowski MT, Brevetti LS, Hall TS| | View in PubMed
  238. A comparison analysis of anti-tumor efficacy of adenoviral gene replacement therapy (p14ARF and p16INK4A) in human mesothelioma cells.
    Yang CT, You L, Lin YC, Lin CL, Mccormick F, Jablons DM| | View in PubMed
  239. Emergent surgery for massive pulmonary embolism on the basis of clinical diagnosis.
    Brevetti GR, O'Brien B, Coomer CL, Hall TS, Brevetti LS, Jablons DM| | View in PubMed
  240. Contralateral tension pneumothorax during one-lung ventilation for lobectomy: diagnosis aided by fiberoptic bronchoscopy.
    Malik S, Shapiro WA, Jablons D, Katz JA| | View in PubMed
  241. Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization: implications of the phosphatidylinositol 3-kinase pathway.
    Massion PP, Kuo WL, Stokoe D, Olshen AB, Treseler PA, Chin K, Chen C, Polikoff D, Jain AN, Pinkel D, Albertson DG, Jablons DM, Gray JW| | View in PubMed
  242. Induction of apoptosis in mesothelioma cells by antisurvivin oligonucleotides.
    Xia C, Xu Z, Yuan X, Uematsu K, You L, Li K, Li L, McCormick F, Jablons DM| | View in PubMed
  243. Aberrations in the fragile histidine triad (FHIT) gene in idiopathic pulmonary fibrosis.
    Uematsu K, Yoshimura A, Gemma A, Mochimaru H, Hosoya Y, Kunugi S, Matsuda K, Seike M, Kurimoto F, Takenaka K, Koizumi K, Fukuda Y, Tanaka S, Chin K, Jablons DM, Kudoh S| | View in PubMed
  244. p14(ARF) modulates the cytolytic effect of ONYX-015 in mesothelioma cells with wild-type p53.
    Yang CT, You L, Uematsu K, Yeh CC, McCormick F, Jablons DM| | View in PubMed
  245. Prostaglandin E2 and vasoactive intestinal peptide increase vascular endothelial cell growth factor mRNAs in lung cancer cells.
    Casibang M, Purdom S, Jakowlew S, Neckers L, Zia F, Ben-Av P, Hla T, You L, Jablons DM, Moody TW| | View in PubMed
  246. Stage II (N1) lung cancer.
    Choy O, Jahan T, Roach M, You L, Jablons D| | View in PubMed
  247. The impact of changes in radiographic abnormalities in organ donors on successful lung donation.
    McCowin M, Hall TS, Babcock W, Solinger LL, Hall KW, Jablons D| | View in PubMed
  248. Expression sequence tag-specific full-length cDNA cloning: actin cDNAs.
    Xu Z, Jablons DM, Gruenert DC| | View in PubMed
  249. Giant tumors of the chest: preoperative embolization and resection.
    Brevetti GR, Sasse KC, Khan JH, Wilson MW, Clary-Macy C, Brevetti LS, Hall TS, Jablons D| | View in PubMed
  250. Positron emission tomography with f18-fluorodeoxyglucose in the staging and preoperative evaluation of malignant pleural mesothelioma.
    Schneider DB, Clary-Macy C, Challa S, Sasse KC, Merrick SH, Hawkins R, Caputo G, Jablons D| | View in PubMed
  251. Adenovirus-mediated p14(ARF) gene transfer in human mesothelioma cells.
    Yang CT, You L, Yeh CC, Chang JW, Zhang F, McCormick F, Jablons DM| | View in PubMed
  252. ONYX-015 works synergistically with chemotherapy in lung cancer cell lines and primary cultures freshly made from lung cancer patients.
    You L, Yang CT, Jablons DM| | View in PubMed
  253. Pulmonary placental transmogrification: diagnosis and treatment.
    Brevetti GR, Clary-Macy C, Jablons DM| | View in PubMed
  254. Tumor-derived EMMPRIN (extracellular matrix metalloproteinase inducer) stimulates collagenase transcription through MAPK p38.
    Lim M, Martinez T, Jablons D, Cameron R, Guo H, Toole B, Li JD, Basbaum C| | View in PubMed
  255. Giant solitary fibrous tumor of the pleura.
    Khan JH, Rahman SB, Clary-Macy C, Kerlan RK, George TI, Hall TS, Jablons DM| | View in PubMed
  256. Resection and IORT followed by three-dimensional conformal radiotherapy with or without adjuvant chemotherapy for malignant mesothelioma.
    Jablons DM, Roach M, Jahan T, Cameron RB| | View in PubMed
  257. The heimlich device in thoracic surgery.
    Key SP, Cameron RC, Jablons DM| | View in PubMed
  258. Interleukin 6 reduces lipoprotein lipase activity in adipose tissue of mice in vivo and in 3T3-L1 adipocytes: a possible role for interleukin 6 in cancer cachexia.
    Greenberg AS, Nordan RP, McIntosh J, Calvo JC, Scow RO, Jablons D| | View in PubMed
  259. IL-2-based immunotherapy alters circulating neutrophil Fc receptor expression and chemotaxis.
    Jablons D, Bolton E, Mertins S, Rubin M, Pizzo P, Rosenberg SA, Lotze MT| | View in PubMed
  260. Interleukin-3 induces proliferation but not lymphokine activated killer activity from human and murine mononuclear cells.
    Jablons DM, Donohue R, Kawakami Y, Young JD, Lotze MT| | View in PubMed
  261. Antitumor activity of recombinant interleukin 6 in mice.
    Mulé JJ, McIntosh JK, Jablons DM, Rosenberg SA| | View in PubMed
  262. In vivo induction of IL-6 by administration of exogenous cytokines and detection of de novo serum levels of IL-6 in tumor-bearing mice.
    McIntosh JK, Jablons DM, Mulé JJ, Nordan RP, Rudikoff S, Lotze MT, Rosenberg SA| | View in PubMed
  263. Metastasectomy for soft tissue sarcoma. Further evidence for efficacy and prognostic indicators.
    Jablons D, Steinberg SM, Roth J, Pittaluga S, Rosenberg SA, Pass HI| | View in PubMed
  264. IL-6/IFN-beta-2 as a circulating hormone. Induction by cytokine administration in humans.
    Jablons DM, Mulé JJ, McIntosh JK, Sehgal PB, May LT, Huang CM, Rosenberg SA, Lotze MT| | View in PubMed
  265. Induction of interferon-beta 2/interleukin-6 (IL-6) by cytokine administration and detection of circulating interleukin-6 in the tumor-bearing state.
    Jablons DM, McIntosh JK, Mulé JJ, Nordan RP, Rudikoff S, Lotze MT| | View in PubMed
  266. Derivation of cells with lytic activity against fresh and cultured tumors from human bone marrow.
    Jablons DM, Lotze MT| | View in PubMed